Report
FDA programs on the horizon: What biopharma companies need to know
Discover the U.S. FDA’s groundbreaking Commissioner’s National Priority Voucher (CNPV) program, a new initiative designed to accelerate drug review timelines to as little as 1–2 months for eligible biopharmaceuticals.
With a focus on addressing public health crises, advancing innovative cures, and strengthening U.S. supply chain resiliency, the CNPV program offers a unique opportunity for biopharma companies to bring life-saving treatments to market faster.
The program reflects the FDA’s commitment to balancing innovation, affordability, and regulatory rigor while navigating the evolving healthcare landscape. Learn how your organization can adapt to this new regulatory paradigm, evaluate risks and opportunities, and prepare for success in an agile and fast-paced environment.
Download the report to learn more!
The program reflects the FDA’s commitment to balancing innovation, affordability, and regulatory rigor while navigating the evolving healthcare landscape. Learn how your organization can adapt to this new regulatory paradigm, evaluate risks and opportunities, and prepare for success in an agile and fast-paced environment.
Download the report to learn more!
Pardot Form
Connect with our team
Our commitment to helping clients achieve market access plays a crucial role in patients’ access to affordable, diverse, and effective therapies so they can achieve their best potential health outcomes. Connect with our team of experts to discover how we can help support your goals.
